News
Video
Author(s):
Oncologists discuss the selection of the optimal frontline therapy for renal cell carcinoma, considering factors like response rates, progression, quality of life, and long-term results.
Maughan Spotlights Ways to Reengage the Immune System and Debulking Approaches in RCC
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
Perioperative Nivolumab Regimen Improves EFS, Resection Rates in Stage III N2/non-N2 NSCLC
FDA Approval Insights: Ponatinib in Ph+ ALL
Consolidation Durvalumab to Become New SOC for LS-SCLC After Chemoradiation
Revisit Every OncLive On Air Episode From May 2024
Talquetamab Produces Responses in R/R Myeloma After Prior T-Cell–Directed Therapies
Lurbinectedin Plus Irinotecan Is Safe, Prolongs Responses in High-Risk, Pretreated SCLC
Axi-Cel Shows Safety, Clinical Activity in R/R Primary and Secondary CNS Lymphomas
Amphiphile Lymph Node–Targeted Vaccine Is Safe and Bolsters T-Cell Responses in MRD+ PDAC and CRC